CollabRx, Sengenics Partner on Cancer Diagnostics

Share on facebook
Share on whatsapp
Share on twitter
Share on linkedin

CollabRx today announced a deal with Sengenics to incorporate each other’s products into molecular diagnostics tests and reports aimed at cancer.


Under the terms of the agreement, Sengenics will integrate CollabRx’s interpretive content resources into its cancer exome sequencing tests and reports. The combined products are being designed “to seamlessly pair test results with clinically actionable and dynamically updated knowledge on the clinical impact of specific tumor genetic profiles and associated therapeutic strategies, such as drugs and clinical trials,” CollabRx said.


The San Francisco-based data analytics firm added that it will provide content in a software-as-a-service-based business model.


The deal, CollabRx said, extends its presence into three continents: North America, Europe, and Asia. Financial and other terms of the agreement were not disclosed.


Today’s announcement follows a test and medical information development partnership between CollabRx and OncoDNA that was announced last week.


Based in Kuala Lumpur, Malaysia, Sengenics offers genomics- and proteomics-based diagnostics.


“Our joint solution’s ability to provide insights from CollabRx’s clinical practitioner network represents critical and timely value to physicians when they are interpreting test results,” Arif Anwar, executive director of Sengenics, said in a statement.



Related news link:

Sign up for our Newsletter

Insert your email to sign up to our newsletter.


Resources to access our technology


Your technical questions - answered


One technology - endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361